Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma

Endocrine-Related Cancer

Volumn 19, Issue 6, 2012, Pages 779-784

  Bullock, M ^a   O'Neill, C ^b   Chou, A ^c   Clarkson, A ^b   Dodds, T ^b   Toon, C ^b   Sywak, M ^b   Sidhu, S B ^a,b   Delbridge, L W ^b   Robinson, B G ^a,b   Learoyd, D L ^a,b   Capper, D ^d,e   Von Deimling, A ^d,e   Clifton Bligh, R J ^a,b,f   Gill, Anthony J ^b,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN B RAF V600E; UNCLASSIFIED DRUG;

ARTICLE; FALSE NEGATIVE RESULT; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID CARCINOMA;

ANTIBODIES, MONOCLONAL; CARCINOMA; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS; TISSUE EMBEDDING;

EID: 84869220840     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0239     Document Type: Article

References (15)

1. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A et al. 2010 Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. Journal of Clinical Endocrinology and Metabolism 95 4197-4205. (doi:10.1210/jc.2010-0337)
2. Capper D, Preusser M, Habel A, Sahm F, Ackerman U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H & von Deimling A 2011 Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathologica 122 11-19. (doi:10.1007/s00401-011-0841-z)
3. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW & Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute 95 625-627. (doi:10.1093/jnci/95.8. 625)
4. Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, Berti P, Materazzi G, Miccoli P, Santoro M et al. 2007 The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 3511-3516. (doi:10.1210/jc.2007-0594)
5. V600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism 97 2333-2340. (doi:10.1210/jc.2011-3106)
6. V600E is a rare clonal event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 517-524. (doi:10.1210/jc.2011-0618)
7. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibiru D, Bastian B & Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery 246 466-470 (discussion 470-471). (doi:10.1097/SLA.0b013e318148563d)
8. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457. (Pubitemid 36373628)
9. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Biederle B, von Deimling A, Birner P & Preusser M 2012 Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. American Journal of Surgical Pathology 36 844-850. (doi:10.1097/PAS.0b013e318246b527)
10. Lee JH, Lee ES & Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110 38-46. (doi:10.1002/cncr.22754)
11. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P et al. 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 4085-4090. (doi:10.1210/jc.2007-1179)
12. Nikiforov YE & Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. Nature Reviews. Endocrinology 7 569-580. (doi:10.1038/nrendo. 2011.142)
13. V600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148 1139-1145 (discussion 1145-1146). (doi:10.1016/j.surg.2010.09.005)
14. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762. (doi:10.1210/er.2007-0007)
15. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6637. (doi:10.1210/jc.2005-0987)